SuPAR, a potential inflammatory mediator in psoriasis pathogenesis
- 19 June 2020
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (10), 1705-1712
- https://doi.org/10.1111/1440-1681.13365
Abstract
Psoriasis is an inflammatory skin disorder that is strongly associated with the metabolic syndrome. The sole reliance on clinical examination to guide prognostication and treatment is insufficient at best; accurate diagnostic and prognostic psoriatic molecular biomarkers are needed. Soluble urokinase plasminogen activator receptor (suPAR) has been implicated in inflammation. The aim of this study is to determine whether suPAR plays a role in the pathogenesis of psoriasis and whether an association exists between suPAR levels, disease severity, and other variables like insulin, erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP). This study also compares the pattern of uPAR staining in healthy vs psoriatic skin: 39 psoriatic and 30 control subjects were included. Two biopsies (affected and unaffected skin) and one biopsy were taken from psoriasis patients and healthy controls, respectively, with uPAR staining of all skin biopsies. Blood samples from all subjects were obtained to determine suPAR, ESR, CRP, and fasting insulin levels. uPAR staining was prominent in unaffected skin from psoriasis patients and healthy individuals vs weak/absent uPAR staining in psoriatic skin. CRP, ESR and suPAR levels were not significantly elevated in the mild psoriasis group compared to healthy controls. The loss of epidermal uPAR is suggestive of its tentative role in the pathogenesis of psoriasis. Patients with mild–moderate psoriasis possibly lack the powerful association attributed to metabolic syndrome in psoriatic patients. Further studies on larger cohorts are needed to ascertain the validity of the mentioned conclusions.Keywords
This publication has 27 references indexed in Scilit:
- Metabolic syndrome in patients with psoriasis: A comparative studyIndian Dermatology Online Journal, 2014
- Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk ScoreInternational Journal of Cardiology, 2013
- C‐reactive protein in psoriasis: a review of the literatureJournal of the European Academy of Dermatology and Venereology, 2013
- Psoriasis and the Risk of Diabetes MellitusJAMA Dermatology, 2013
- Erythrocyte sedimentation rate as a marker for coronary heart diseaseVascular Health and Risk Management, 2012
- The immune marker soluble urokinase plasminogen activator receptor is associated with new‐onset diabetes in non‐smoking women and menDiabetic Medicine, 2011
- Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid ConditionsJournal of Investigative Dermatology, 2010
- Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid ArthritisInflammation, 2009
- Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptideThe EMBO Journal, 2005
- Cytokine imbalance in acute coronary syndromeCurrent Opinion in Pharmacology, 2004